RVL Pharmaceuticals plc (RVLPQ)

OTCMKTS: RVLPQ · Delayed Price · USD
0.0001
0.00 (0.00%)
Feb 28, 2024, 4:00 PM EST - Market closed
Market Cap 9.94K
Revenue (ttm) 36.92M
Net Income (ttm) -68.27M
Shares Out 99.37M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,220
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0002
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About RVLPQ

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 125
Stock Exchange OTCMKTS
Ticker Symbol RVLPQ
Full Company Profile

Financial Performance

In 2022, RVLPQ's revenue was $49.72 million, an increase of 184.10% compared to the previous year's $17.50 million. Losses were -$51.69 million, -20.38% less than in 2021.

Financial Statements

News

RVL Completes Financial Restructuring

Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities

3 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries

Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries ...

5 months ago - GlobeNewsWire

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Exe...

6 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (ox...

7 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendme...

7 months ago - GlobeNewsWire

RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET -- -- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --

7 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Provides Business Update

BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the commerciali...

8 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting

BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to app...

9 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first ...

10 months ago - GlobeNewsWire

RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update

BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxy...

10 months ago - GlobeNewsWire

RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards

Selected from 10,000 Entrants Selected from 10,000 Entrants

11 months ago - GlobeNewsWire

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, o...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update

Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for ful...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Exe...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update

-- Third quarter 2022 UPNEEQ ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales

--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product sales ...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exe...

1 year ago - GlobeNewsWire

Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plc

DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nas...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update

-- Second quarter 2022 UPNEEQ ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings --

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing

-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at closin...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial Update

Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results

--  Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- --  Second quarter 2022 net product s...

1 year ago - PRNewsWire

RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting

BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company's Annua...

1 year ago - GlobeNewsWire

RVL Pharmaceuticals plc to Present at Upcoming Conferences

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exec...

1 year ago - GlobeNewsWire